Antibiotic fidaxomicin is an RdRp inhibitor as a potential new therapeutic agent against Zika virus
Abstract Background Zika virus (ZIKV) infection is a global health problem, and its complications, including congenital Zika syndrome and Guillain-Barré syndrome, constitute a continued threat to humans. Unfortunately, effective therapeutics against ZIKV infection are not available thus far. Methods...
Main Authors: | Jie Yuan, Jianchen Yu, Yun Huang, Zhenjian He, Jia Luo, Yun Wu, Yingchun Zheng, Jueheng Wu, Xun Zhu, Haihe Wang, Mengfeng Li |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-07-01
|
Series: | BMC Medicine |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12916-020-01663-1 |
Similar Items
-
Monoclonal antibody against EV71 3Dpol inhibits the polymerase activity of RdRp and virus replication
by: Yaoming Li, et al.
Published: (2019-01-01) -
The potential of Paritaprevir and Emetine as inhibitors of SARS-CoV-2 RdRp
by: Arun Bahadur Gurung, et al.
Published: (2021-02-01) -
SARS-CoV-2 RdRp Inhibitors Selected from a Cell-Based SARS-CoV-2 RdRp Activity Assay System
by: Jung Sun Min, et al.
Published: (2021-08-01) -
RdRp mutations are associated with SARS-CoV-2 genome evolution
by: Doğa Eskier, et al.
Published: (2020-07-01) -
Usutu Virus NS5: Characterization of Polymerase Activity, Protein–Protein Interaction and Cellular Localization %MCEPASTEBIN%
by: Laura Albentosa-González, et al.
Published: (2020-06-01)